MDSpire - Takeaway
Feature

Advancing Precision Oncology: What Pooled Trial Data Reveal About 177 Lu-PSMA-617 in mCRPC

Radiopharmaceutical therapy is rapidly reshaping the treatment landscape for advanced prostate cancer.

  • March 31, 2026

  • 3 min

Share

  • 1

    177Lu-PSMA-617 targets advanced prostate cancer.

  • 2

    Pooled analysis from seven trials with >2,500 patients.

  • 3

    36% reduction in disease progression risk.

  • 4

    Inconsistent overall survival results due to trial variability.

  • 5

    Emphasis on need for multidisciplinary care in therapy delivery.

  • 6

    Strengthened confidence in treatment's reproducibility across patient populations.

Original Source(s)

Advancing Precision Oncology: What Pooled Trial Data Reveal About 177 Lu-PSMA-617 in mCRPC

  • March 31, 2026

Related Content

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsore...

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

“Adjuvant pembrolizumab plus belzutifan demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs pembrolizumab plus placebo in patients with clear cel...

It's Like PCR, But Better

Geoff Smith introduces the mcPCR method for methylated DNA analysis that is expanding the potential of epigenetics for disease detection